多西他赛联合卡培他滨在晚期非小细胞肺癌二线化疗中的疗效及安全性观察

目的观察多西他赛联合卡培他滨在晚期非小细胞肺癌(NSCLC)二线治疗中的疗效及安全性。方法本院26例以铂类为主的晚期NSCLC患者一线化疗失败后,对PS评分较好(0~1分)的患者给予多西他赛+希罗达联合化疗。评价客观疗效、生存时间及不良反应。结果 26例患者中,未见完全缓解(CR)患者,部分缓解(PR)5例,疾病稳定(SD)10例,疾病进展(PD)11例。中位无进展生存时间5.2个月,中位总生存时间9.6个月,1年生存率26.92%。5例出现Ⅲ~Ⅳ度中性粒细胞下降,1例出现Ⅲ度手足综合征。结论多西他赛联合卡培他滨在晚期NSCLC的二线治疗中是一个有效的化疗方案,毒副反应可以耐受。

Efficacy and safety of docetaxel plus capecitabine as second-line treatment in treating patients with advanced non-small cell lung cancer

Objective To observe efficacy and safety of docetaxel plus capecitabine as second-line treatment in treating patients with advanced non-small cell lung cancer(NSCLC).Methods 26 patients who failed in platinum-based first-line chemotherapy with good performance status(scoring 0-1) were treated with docetaxel plus capecitabine.The objective curative effect,survival time and adverse reactions were evaluated.Results Among the 26 patients,there were 5 cases of PR,10 cases of SD,11 cases of PD.The median progression-free survival time was 5.2 months,the median overall survival time was 9.6 months,and the 1-year survival rate was 26.92%.5 cases had grade Ⅲ～Ⅳ neutropenia,only 1 case had grade Ⅲ hand-foot syndrome.Conclusion Combination of docetaxel and capecitabine as second-line treatment is an effective chemotherapy regimen for patients with advanced non-small cell lung cancer,and its side effects also can be tolerated.